ReviewMolecules (Basel, Switzerland)2020
Mycetoma and Chromoblastomycosis: Perspective for Diagnosis Improvement Using Biomarkers.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Mycetoma Epidemiology and Clinical Findings in Mogadishu, Somalia.Journal of tropical medicine · 2025Article
- Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.Journal of fungi (Basel, Switzerland) · 2024Article
- Identification of Chromoblastomycosis and Phaeohyphomycosis Agents through ITS-RFLP.Journal of fungi (Basel, Switzerland) · 2024Article
- Nanoparticles assisted intra and transdermic delivery of antifungal ointment: an updated review.Discover nano · 2024Review
- Chromoblastomycosis: New Perspective on Adjuvant Treatment with Acitretin.Diseases (Basel, Switzerland) · 2023Article
- Skin Mycetoma in an 11-Year-Old African Boy: Case Presentation with Emphasis on Histopathological Features and Differential Diagnosis.Dermatopathology (Basel, Switzerland) · 2021Article
- Diagnosing point-of-care diagnostics for neglected tropical diseases.PLoS neglected tropical diseases · 2021Review
- Subcutaneous Mycoses in Travelers.Current tropical medicine reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycetoma and chromoblastomycosis are both chronic subcutaneous infectious diseases that pose an obstacle to socioeconomic development. Besides the therapeutic issue, the diagnosis of most neglected tropical diseases (NTD) is challenging. Confirmation using direct microscopy and culture, recognized as WHO essential diagnostic tests, are limited to specialized facilities. In this context, there is a need for simple user-friendly diagnostic tests to be used in endemic villages.
methodsThis review discuss the available biomarkers that could help to improve the diagnostic capacity for mycetoma and chromoblastomycosis in a theoretical and practical perspective.
resultsA lack of research in this area has to be deplored, mainly for mycetoma. Biomarkers based on the immune response (pattern of leucocytes, antibody detection), the dermal involvement (extracellular matrix monitoring, protein expression), and the presence of the infectious agent (protein detection) are potential candidates for the detection or follow-up of infection.
conclusionConfirmatory diagnosis based on specific diagnostic biomarkers will be the basis for the optimal treatment of mycetoma and chromoblastomycosis. It will be part of the global management of NTDs under the umbrella of stewardship activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.